**REFERENCES**

Donor qualification requirements are located in 21 CFR 1271, Subpart C – Donor Eligibility.

Listed below are FDA final rules and guidance documents:

U.S. Department of Health and Human Services, Food and Drug Administration, Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Final Rule (69 FR 29785, May 25, 2004)

https://www.gpo.gov/fdsys/pkg/FR-2004-05-25/pdf/04-11245.pdf

U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) dated August 2007.

https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM091345.pdf

U.S. Department of Health and Human Services, Food and Drug Administration,

Guidance for Industry: Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products dated May 2018.

http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM488582.pdf

U.S. Department of Health and Human Services, Food and Drug Administration,

Guidance for Industry: Revised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products Who Have Received Human-Derived Clotting Factor Concentrates dated November 2016.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-determining-eligibility-donors-human-cells-tissues-and-cellular-and-tissue>

U.S. Department of Health and Human Services, Food and Drug Administration,

Guidance for Industry: Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) dated May 2017

<https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM372084.pdf>

U.S. Department of Health and Human Services, Food and Drug Administration,

Guidance for Industry: Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products dated August 2016

<https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/UCM516650.pdf>

Additional references include:

The Yellow Book, “Health Information for International Travel”, CDC. Includes information on malaria. <https://wwwnc.cdc.gov/travel/page/yellowbook-home>

AABB Standards for Cellular Therapy Product Services, current edition

FACT/JACIE International Standards for Cellular Therapy Product Collection, Processing & Administration, current edition